References

Filters: Filter is   [Clear All Filters]
B
Borgia SM, Dearden J, Lurie Y. Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis [LB-15]. The Liver Meeting. 2018.
Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;pii: S0168-8278(19):30343-5.
Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008;134:1900-1907.
Boscarino JA, Lu M, Moorman AC, et al. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the chronic hepatitis cohort study (CHeCS). Hepatology. 2015;61(3):802-811.
Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveil. 2010;15(39):19673.
Bourliere M, Gordon SC, Schiff ER, et al. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol. 2018;3(9):559-565.
Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134-2146.
Bourliere M, Bronowicki J, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397-404.
Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58-67.
Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of HCV antibody-positive deceased donor kidneys in the era of direct-acting antiviral therapy. Transplantation. 2018;102:2088-2095.
Boyle A, Marra F, Peters E, et al. Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. J Viral Hepat. 2020;27(4):371-375.
Brau N, Salvatore M, RÍos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44(1):47-55.
Braun DL, Hampel B, Nguyen H. A treatment as prevention trial to eliminate HCV in HIV+ MSM: the Swiss HCVree trial [abstract 81LB]. 25th Conference on Retroviruses and Opportunistic Infections. 2018.
Braun DL, Hampel B, Kouyos R, et al. High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus/hepatitis C virus-coinfected men who have sex with men. Clin Infect Dis. 2019;68(4):569-576. doi:10.1093/cid/ciy547.
Bravo MJ, Vallejo F, Barrio G, et al. HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection. Int J Drug Policy. 2012;23(5):415-419.
Brooks KM, Castillo-Mancilla J, Morrow M, et al. Plasma and intracellular pk and renal safety of TAF 25mg with boosted PIs and LDV/SOF [abstract 449]. Presented at Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. 2020.
Brown RS, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 Weeks in Treatment-Naïve Patients with Chronic HCV Genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 Trial. J Hepatol. 2020;72(3):441-449.
Brown RS, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22(1):24-33.
Brown RS, Hezode C, Wang S, et al. Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study [Abstract LB-7]. The Liver Meeting. 2018.
Brown RS, Buti M, Rodrigues L, et al. Efficacy and safety of 8-week glecaprevir/pibrentasvir in treatment-naive patients with chronic hepatitis c virus genotype 1, 2, 3, 4, 5, or 6 infection and compensated cirrhosis: EXPEDITION-8 complete results [abstract LP9]. Presented at Liver Meeting, 2019; November 8-12. 2019.
Top